polarean Share News (POLX)

TRADING UPDATES: Nexteq confident of meeting full-year expectations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Polarean Imaging shares sink after announcing a costly strategic plan

(Alliance News) - Polarean Imaging PLC shares dropped on Thursday, after the company said it would need to find an additional USD10 million to finance its medium-term ambitions.

IN BRIEF: Polarean Imaging strategic parter raises stake to above 10%

Polarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price.

Polarean gets first de novo order for Xenoview polariser

(Sharecast News) - Lung-focussed MRI technology developer Polarean Imaging said in an update on Thursday that it has received its first de novo order for a new Xenoview polariser.

IN BRIEF: Polarean shares jump on Xenoview polariser order

Polarean Imaging PLC - London-based medical imaging technology developer - Receives its first de novo order for a new Xenoview polariser from an unnamed "top-tier" academic medical centre located in the northeast of the US. Polarean says it continues to have positive meetings and is in active negotiations with additional academic medical centres. Xenoview is a hyperpolarised contrast agent for use with magnetic imaging for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. It was approved for use in the US last year.

AIM WINNERS & LOSERS: Smart Metering accepts offer; order for Polarean

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Polarean Imaging enters strategic partnership with VIDA Diagnostics

(Sharecast News) - Advanced MRI technology specialist Polarean Imaging announced a strategic partnership with a clinical imaging intelligence company VIDA Diagnostics on Friday.

Polarean Imaging partners with Vida Diagnostics on MRI solutions

(Alliance News) - Polarean Imaging PLC on Friday said that it has partnered with Vida Diagnostics Inc to work on advanced magnetic resonance imaging solutions for the lungs.

TRADING UPDATES: Polarean withdraws commercial targets on revenue drop

(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

IN BRIEF: Polarean Imaging announces code price range for Xenoview

Polarean Imaging PLC - London-based medical imaging technology developer - Announces that following statement on August 29, the reimbursement code for the Polarean Xenoview technology has been assigned to a new technology ambulatory payment classification code which corresponds to a payment range of between USD1,201 to USD1,300 as part of the 2023 medicare hospital outpatient prospective payment system final rule. Notes the codes enables healthcare providers a path to bill for "magnetic resonance imaging with inhaled hyperpolarised xenon-129 contrast agent, chest, including preparation and administration of agent."

UK earnings, trading statements calendar - next 7 days

Polarean's Xenoview gets US reimbursement code

(Sharecast News) - Medical device developer Polarean Imaging announced on Tuesday that its Xenoview technology has been granted a new reimbursement code by the US Centers for Medicare and Medicaid Services (CMS).

IN BRIEF: Polarean Imaging product cleared for US Medicare payments

Polarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean's Xenoview or 'xenon XE 129' magnetic resonance imaging technology. Code "enables healthcare providers a path to bill for 'magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent'." Polarean expects to be informed of the new code's payment level "in the coming weeks".

IN BRIEF: Polarean hails US FDA approval on Philips MRI configuration

Polarean Imaging PLC - London-based medical imaging technology company - Receives 510(k) clearance from the US Food & Drug Administration for its specialised magnetic resonance imaging chest coil. The coil may now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 nuclei.